Genesis Therapeutics is a Stanford University spin-off.

Genesis Therapeutics, an AI drug discovery company, has secured a $200 million Series B funding round to advance its AI-powered drug development pipeline into clinical testing. Founded in 2019 as a spinoff from Stanford University, Genesis focuses on utilizing its deep learning platform called GEMS to design small-molecule drug compounds and predict their interactions with the body, particularly with flexible or challenging proteins.

This funding round, which was oversubscribed, is a significant increase from its previous $52 million Series A funding in 2020. Existing investors, including Rock Springs Capital, T. Rowe Price Associates, Menlo Ventures, Radical Ventures, and Andreessen Horowitz, as well as new investors like a16z Bio + Health, Fidelity Management & Research Company, BlackRock, and Nvidia’s VC arm, NVentures, participated in this round. (Fierce Biotech)

Genesis plans to leverage the new capital to propel its AI-enabled programs into clinical testing and expand its drug discovery efforts. The company’s GEMS platform is known for generating novel molecules, predicting properties, and targeting previously challenging protein structures.

“GEMS is uniquely capable of identifying and enabling drug candidates for challenging, data-poor, and previously undruggable targets, thereby allowing Genesis to make progress towards breakthrough treatments with the potential for transformative impact across significant and underserved patient populations,” Genesis said in a statement.

Founded by Professor Vijay Pande from Stanford University, Genesis is led by CEO Evan Feinberg and has collaborations with Genentech and Eli Lilly.

Related Story:  Atomic AI Closes $35M Series ‘A’ For RNA Drug Discovery